nafamostat has been researched along with Acute Kidney Failure in 12 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding." | 7.78 | The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. ( Baek, NN; Huh, W; Jang, HR; Kim, DJ; Kim, YG; Lee, JE; Oh, HY, 2012) |
| " The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding." | 3.78 | The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. ( Baek, NN; Huh, W; Jang, HR; Kim, DJ; Kim, YG; Lee, JE; Oh, HY, 2012) |
| "Nafamostat mesilate provided sufficient filter survival without causing major bleeding complications despite the prolongation of APTT." | 3.77 | Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. ( Hosoya, T; Maruyama, Y; Takinami, M; Uchino, S; Yamamoto, H; Yokoyama, K; Yoshida, H, 2011) |
| "Nafamostat has been widely used in acute blood purification at critical care units in Japan." | 2.46 | Anticoagulation in acute blood purification for acute renal failure in critical care. ( Shinoda, T, 2010) |
| " Most units did not change the nutritional dosage according to CRRT use." | 1.91 | Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan. ( Haga, T; Ide, K; Tani, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyaji, MJ | 1 |
| Ide, K | 3 |
| Takashima, K | 1 |
| Maeno, M | 1 |
| Krallman, KA | 1 |
| Lazear, D | 1 |
| Goldstein, SL | 1 |
| Haga, T | 2 |
| Tani, M | 2 |
| Kameda, S | 1 |
| Fujii, T | 1 |
| Ikeda, J | 1 |
| Kageyama, A | 1 |
| Takagi, T | 1 |
| Miyayama, N | 1 |
| Asano, K | 1 |
| Endo, A | 1 |
| Uezono, S | 1 |
| Miyatake, Y | 2 |
| Makino, S | 2 |
| Kubota, K | 2 |
| Egi, M | 2 |
| Mizobuchi, S | 2 |
| Hwang, SD | 1 |
| Hyun, YK | 1 |
| Moon, SJ | 1 |
| Lee, SC | 1 |
| Yoon, SY | 1 |
| Lee, YK | 1 |
| Lee, HW | 1 |
| Choi, KH | 1 |
| Kim, BS | 1 |
| Choi, JY | 1 |
| Kang, YJ | 1 |
| Jang, HM | 1 |
| Jung, HY | 1 |
| Cho, JH | 1 |
| Park, SH | 1 |
| Kim, YL | 1 |
| Kim, CD | 1 |
| Kita, H | 1 |
| Shinoda, T | 1 |
| Maruyama, Y | 1 |
| Yoshida, H | 1 |
| Uchino, S | 2 |
| Yokoyama, K | 1 |
| Yamamoto, H | 1 |
| Takinami, M | 1 |
| Hosoya, T | 1 |
| Baek, NN | 1 |
| Jang, HR | 1 |
| Huh, W | 1 |
| Kim, YG | 1 |
| Kim, DJ | 1 |
| Oh, HY | 1 |
| Lee, JE | 1 |
| Bellomo, R | 1 |
| Morimatsu, H | 1 |
| Morgera, S | 1 |
| Schetz, M | 1 |
| Tan, I | 1 |
| Bouman, C | 1 |
| Macedo, E | 1 |
| Gibney, N | 1 |
| Tolwani, A | 1 |
| Oudemans-van Straaten, H | 1 |
| Ronco, C | 1 |
| Kellum, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01761994] | Phase 4 | 66 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy in the ICU Environment[NCT02341885] | 2,000 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nafamostat and Acute Kidney Failure
| Article | Year |
|---|---|
Anticoagulation in acute blood purification for acute renal failure in critical care.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Critical Care; Guanidines; Hemorrhage; Humans; Ja | 2010 |
2 trials available for nafamostat and Acute Kidney Failure
| Article | Year |
|---|---|
Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Benzamidines; Blood Transfusion; Female; Guanidine | 2014 |
Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Female; Guanidines; Hemorrhage; Humans; Male; Mid | 2015 |
9 other studies available for nafamostat and Acute Kidney Failure
| Article | Year |
|---|---|
Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Child; Citrates; Citric Acid; Continuous Renal Re | 2022 |
Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan.
Topics: Acute Kidney Injury; Anticoagulants; Child; Continuous Renal Replacement Therapy; Cross-Sectional St | 2023 |
Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan.
Topics: Acute Kidney Injury; Anticoagulants; Child; Continuous Renal Replacement Therapy; Cross-Sectional St | 2023 |
Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan.
Topics: Acute Kidney Injury; Anticoagulants; Child; Continuous Renal Replacement Therapy; Cross-Sectional St | 2023 |
Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan.
Topics: Acute Kidney Injury; Anticoagulants; Child; Continuous Renal Replacement Therapy; Cross-Sectional St | 2023 |
Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study.
Topics: Acute Kidney Injury; Adult; Anticoagulants; Blood Coagulation; Citric Acid; Continuous Renal Replace | 2023 |
Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
Topics: Acute Kidney Injury; Adult; Benzamidines; Blood Coagulation; Cohort Studies; Female; Follow-Up Studi | 2017 |
Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamidines; Female; Guanidine | 2013 |
Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Benzamidines; Critical Care; Female; G | 2016 |
Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Benzamidines; Cr | 2011 |
The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Female; Fibrinolysin; Follow-Up Studies; Guanidin | 2012 |
Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Arrhythmias, Cardiac; Benzamidines; Citrates; Drug Utiliz | 2007 |